Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Scientists from the Department of Oncology have equipped a virus that kills carcinoma cells with a protein so it can also target and kill adjacent cells that are tricked into shielding the cancer from the immune system.

One of the problems we face in killing tumours is that the tumours often recruit healthy cells to help them grow and to protect them from attack.  In this case tumours often recruit fibroblasts to help them shape their local environment and protect them from the immune system.

Dr Fisher and Dr Freedman have engineered a virus so that it both attacks tumour cells directly, and also attacks the fibroblasts, which are supporting the tumour.  The virus attacks the tumour cells and in doing so forces, the tumour cells to make a protein, which binds to fibroblasts and sticks them to and immune cell called a T-cell.  The T-cells are triggered to attack and destroy the fibroblasts helping to undermine the support that the tumour is replying on.

People have tried to attack fibroblast before, but this often causes widespread destruction of fibroblasts, whereas this work targets the tumour-associated fibroblasts which are supporting the tumour.

Read more (University of Oxford website)

Similar stories

Cancer patients remain at higher risk of severe COVID-19 disease despite third dose booster vaccine

A large population-level assessment reveals third dose COVID-19 vaccination is effective for most patients with cancer, but effectiveness is lower than in the general population, particularly in patients who have undergone recent chemotherapy and those with lymphoma.

Time-varying nature of clinical risk factors for pancreatic cancer may aid earlier diagnosis

Body mass index, blood tests, comorbidities and medication use are temporally associated with cancer risk in the three years before a pancreatic cancer diagnosis.

Population-scale study highlights ongoing risk of COVID-19 in some cancer patients despite vaccination

COVID-19 vaccination is effective in most cancer patients, but the level of protection against COVID-19 infection, hospitalisation and death offered by the vaccine is less than in the general population and vaccine effectiveness wanes more quickly.

OUH agrees long COVID research collaboration with Polarean

The collaboration will look at understanding the long-term effects of COVID-19 through cutting-edge MRI analysis.

Lung abnormalities found in long COVID patients with breathlessness

Researchers have identified abnormalities in the lungs of long COVID patients who are experiencing breathlessness that cannot be detected with routine tests.